RyCarma Therapeutics
NY - ArdsleyBiotechnology
Focus: RyCarma Therapeutics is a public biotechnology company focused on developing small molecules that repair leaky Ryanodine Receptor calcium channels for rare cardiac and muscular diseases. The company operates as a focused clinical-stage biotech with a specialized mechanism of action.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About RyCarma Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow RyCarma Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
S48168
RYR-1 MyopathyClinical Trials (1)
NCT04141670S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)
Phase 1Help build intelligence for RyCarma Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.